Latest News – PSNC Main site Pharmaceutical Services Negotiating Committee

  • NUMSAS: are you claiming correctly?
    Posted by alkharsanz on 25th April 2019 at 11:03 am

    Following the extension of the NHS Urgent Medicine Supply Advanced Service (NUMSAS) pilot until September 30th 2019, community pharmacy contractors are reminded of the need to follow the correct process when claiming for payment. Contractors may find PSNC Briefing 034/17 useful when claiming for payment as it contains a checklist for completing an FP10DT EPS... […]

  • Class 4 MHRA Drug Alert – Ativan 4mg/1ml Solution for injection (Lorazepam) (Pfizer Limited) Caution in use
    Posted by welbournes on 24th April 2019 at 2:42 pm

    Drug Alert No: EL (19) A/10 Date Issued: 24th April 2019 The Medicines and Healthcare products Regulatory Agency (MHRA) has issued a class 4 drug alert for certain batches of Ativan 4mg/1ml Solution for Injection (Lorazepam) (Pfizer Limited) Ativan 4mg/1ml Solution for Injection (Lorazepam) (Pfizer Limited) PL 00057/1279 Batch Number Expiry Date Pack Size First... […]

  • April 2019 Price Concessions – 2nd update
    Posted by welbournes on 18th April 2019 at 3:01 pm

    Department of Health and Social Care (DHSC) has today granted the following list of price concessions: Drug Pack size Price Concession Betahistine 8mg tablets 84 £1.38 Betahistine 16mg tablets 84 £2.70 Candesartan 16mg tablets 28 £2.90 Carvedilol 12.5mg tablets 28 £2.10 Celecoxib 200mg capsules 30 £13.76 Diamorphine 10mg powder for solution for injection ampoules 5... […]

  • MHRA Drug Safety Update April 2019
    Posted by welbournes on 17th April 2019 at 10:20 am

    Date issued: 16th April 2019 A new Medicines and Healthcare products Regulatory Agency (MHRA) Drug Safety Update (Vol 12 Issue 9 March 2019:1) has been published and includes articles on: Yellow fever vaccine (Stamaril) and fatal adverse reactions: extreme caution needed in people who may be immunosuppressed and those 60 years and older. Valproate medicines... […]

  • April 2019 Price Concessions – 1st update
    Posted by Mitesh on 16th April 2019 at 3:30 pm

    Department of Health and Social Care (DHSC) has today granted the following initial list of price concessions: Drug Pack size Price Concession Amiloride 5mg tablets 28 £9.50 Baclofen 10mg tablets 84 £1.67 Candesartan 32mg tablets 28 £2.40 Carvedilol 3.125mg tablets 28 £1.21 Carvedilol 25mg tablets 28 £3.26 Celecoxib 100mg capsules 30 £3.29 Chloramphenicol 0.5% […]

  • A summary of the Network Contract Directed Enhanced Service (DES) 2019/20
    Posted by mabbuttm on 16th April 2019 at 10:30 am

    At the end of January 2019, NHS England published a five-year framework for GP services agreed with the British Medical Association (BMA) General Practitioners Committee (GPC) in England and supported by Government. One of the major changes in the contract is the introduction of the Network Contract as a Directed Enhanced Service (DES). This will enable general... […]

  • DHSC EU Exit Communication
    Posted by fergusonj on 12th April 2019 at 4:52 pm

    Community pharmacy teams will be aware that Government has agreed a further extension of the EU exit date to 31st October 2019. This means that today, 12th April, is no longer the legal default to leave the EU without a deal. If the Withdrawal Agreement is ratified by both sides before the 31st October, then... […]

  • Shortage of Labetalol tablets
    Posted by welbournes on 12th April 2019 at 4:13 pm

    Specialist Pharmacy Service (SPS) advises that there is currently a shortage of Labetalol 50mg, 100mg, 200mg and 400mg tablets. The two suppliers of Labetalol tablets in the UK are experiencing supply issues. Availability is expected to be interrupted until early – mid May. Further advice can be found here on the SPS website.   &nbs […]

  • Prescription submission reminder – Stickers on prescriptions
    Posted by hackettg on 11th April 2019 at 11:09 am

    NHSBSA have raised concerns over the increasing number of prescriptions they are receiving with stickers attached to them. This causes particular issues where the stickers are obscuring the prescriber details on the bottom of prescription forms. Prescriber details must be visible for relevant costs to be attributed to the appropriate CCG. If the prescriber details... […]

  • Case study: Pharmacy domiciliary service helps integrate care for housebound patients
    Posted by alkharsanz on 11th April 2019 at 10:50 am

    A research paper about a community pharmacist-led holistic domiciliary Medicines Use Review (MUR) service has been published in the Research in Social and Administrative Pharmacy journal. The study, Can community pharmacy successfully bridge the gap in care for housebound patients? concludes that domiciliary visits by community pharmacists can highlight the diverse care needs of housebound... […]